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Abstract
Differentiated cells can be reprogrammed through the formation of heterokaryons and hybrid cells when fused with
embryonic stem (ES) cells. Here, we provide evidence that conversion of human B-lymphocytes towards a multipotent state
is initiated much more rapidly than previously thought, occurring in transient heterokaryons before nuclear fusion and cell
division. Interestingly, reprogramming of human lymphocytes by mouse ES cells elicits the expression of a human ES-
specific gene profile, in which markers of human ES cells are expressed (hSSEA4, hFGF receptors and ligands), but markers
that are specific to mouse ES cells are not (e.g., Bmp4 and LIF receptor). Using genetically engineered mouse ES cells, we
demonstrate that successful reprogramming of human lymphocytes is independent of Sox2, a factor thought to be required
for induced pluripotent stem (iPS) cells. In contrast, there is a distinct requirement for Oct4 in the establishment but not the
maintenance of the reprogrammed state. Experimental heterokaryons, therefore, offer a powerful approach to trace the
contribution of individual factors to the reprogramming of human somatic cells towards a multipotent state.
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Introduction
Reprogramming somatic cells to become ES-like is an
important goal in cell replacement therapy since it affords the
opportunity to generate and use patient-specific ES derived cells as
grafts. Epigenetic reprogramming can be achieved in different
ways including nuclear transfer [1–4] or the forced expression of
one or more transcription factors [5,6]. Retroviral-mediated
expression of four transcriptional regulators, Oct4, Sox2, c-Myc
and Klf4, was shown to drive mouse fibroblasts into an ES-like
(iPS) state, albeit at low frequency [7,8]. Reprogramming of
human fibroblasts has also recently been achieved in a parallel
approach using Oct4, Sox2 and either Nanog plus Lin28 [9] or
Klf4 plus c-Myc [10].These pioneering studies have illustrated the
importance of several factors for iPS, but also suggested that
additional ones may be needed for efficient conversion to
pluripotency. Reprogramming can also be achieved by cellular
fusion, a process that occurs spontaneously in vitro [11], in vivo [12]
and experimentally using specific agents [13]. For example, fusion
of differentiated cells with pluripotent ES cells, embryonic
carcinoma (EC) or embryonic germ (EG) cells, induces the
expression of pluripotency-associated markers in the hybrid cells
[14–18] and chromatin remodelling at specific sites in the somatic
cell genome [14,15,18–21]. While these data show that repro-
gramming occurs through the epigenetic resetting of gene
expression programs in the differentiated cell, it has been unclear
whether nuclear fusion and genome duplication are absolutely
required for successful conversion [22]. Here we investigated the
requirements for, and the stability of, dominant reprogramming of
human B cells by fusion with mouse ES cells. We show that
reprogramming is surprisingly rapid and occurs within hetero-
karyons in which lymphocyte and ES cell nuclei remain spatially
discrete. Furthermore, our data show that while Oct4 is critical for
successful reprogramming of human lymphocytes to an ES-like
state, Sox2 is not required. Thus our data outline an alternative
strategy for defining the factors that are required for inducing a
pluripotent state in human somatic cells.
Results
Reprogramming of Gene Expression Is Initiated in ES Cell
Heterokaryons Prior to Nuclear Fusion
Human B cells were fused with mouse ES cells using
polyethylene glycol (PEG). The nuclear events in fused cells were
monitored by fluorescence microscopy and quantitative RT-PCR
to analyse gene expression (Figure 1). To facilitate the identifica-
tion of fused cells, E14tg2a mouse ES cells were pre-labelled with
DiD and human B cells with DiI and dual-stained cells were
purified by FACS (typically 10–15% of cells, Figure S1A). Human
(B cell-derived) and mouse (ES cell-derived) nuclei were distin-
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labelling, and the proportion of cells containing two discrete
(heterokaryons) or conjoined nuclei (hybrids) was assessed over
time (Figure 1B). Up to 2 days following cell fusion 98–99% of
dual labelled cells were identified as heterokaryons in which a
single human and a single mouse nucleus were evident (illustrated
in Figure 1B, central image). The kinetics of nuclear fusion were
also confirmed by fluorescence in situ hybridization (FISH) analysis
in which probes specific for mouse chromosomes (c-satellite, red)
or human chromosomes (a-satellite, green) were used to detect
interspecies chromosome mixing, indicative of hybrid formation
(Figure S1B and Text S1).
The expression of pluripotency-associated genes and lympho-
cyte-associated genes by human B cell-derived nuclei was assessed
by qRT-PCR, using primers that selectively amplify the human
transcripts. Expression of human Oct4, Nanog, Cripto, Dnmt3b and
Tle1 was detected in cells as early as 1 day after fusion and human
Rex1 after 2 days (Figure 1C and Figure S1C). Although the levels
were low in heterokaryons (,1% of that detected in human ES
cells, cell line NCL1), these increased over time and were
undetectable in non-fused (or self-fused, not shown) human B
cells or control mouse ES cells. Expression of hTert was detected
from day 4 onwards (Figure S1D), while hHprt expression was
equivalent at all stages, as anticipated (Figure 1D). Mouse
lymphocyte-specific gene transcripts (mCD19,m CD37 and
mCD45) were not detected throughout the analysis (not shown),
confirming the dominance of ES cells in conversion [15,18].
Increased expression of human pluripotency-associated genes over
this 8-day period was mirrored by a reduction in expression of
several human lymphocyte-associated genes within the second
(hCD45,h CD37 and hCD19) or third day (hCD20 and hPax5)o f
heterokaryon formation (Figure 1D). Collectively these data show
that upon dominant reprogramming, activation and silencing of
tissue-specific gene programs begins ahead of, and therefore does
not require, nuclear fusion and cell division. In addition, since
these results examine gene expression at the population level, it is
possible that gene expression varied between individual hetero-
karyons and hybrid cells.
As the reprogramming of somatic cells has been previously
shown to result in altered DNA methylation at specific loci
[15,18,21,23], we examined changes in the methylation status of
the human Oct4 gene promoter [24] and as a control, the Igf2/H19
imprinting control region (ICR) [25]. As illustrated in Figure 1E,
human B cells prior to fusion showed high levels of DNA
methylation throughout the hOct4 promoter and across a single
Igf2/H19 allele. Following cell fusion, DNA methylation of hOct4
in reprogrammed B cells declined, consistent with a trend towards
a hypomethylated state as seen in the human ES cell line H1.
Demethylation of the hOct4 promoter was detected prior to
nuclear fusion and cell division, a result that is consistent with
active chromatin remodelling of the locus prior to expression. No
changes in DNA methylation at Igf2/H19 ICR were detected over
this period, consistent with its imprinted status [25].
Induction of a Human ES-Specific Gene Expression Profile
A comparison of the relative abundance of gene-specific
transcripts in reprogrammed human B cells (Figure 2A, right-
hand column), showed a strong similarity with the gene expression
profiles of several human ES cell lines (NCL1 [26], HI, H7, H9
[27]; Figure 2A, left-hand column). For example, while Oct4 was
abundantly expressed in all human and mouse ES cell lines, Nanog
and Cripto expression was consistently much lower than Oct4 (100–
1000 fold) for each of the mouse ES cell lines analysed (OS25,
CCE, E14, ZHBTc4; Figure 2A, middle panel). In human ES cell
lines however, Oct4, Nanog and Cripto transcripts were similarly
abundant, consistent with that seen in reprogrammed human B
cells. Expression of some pluripotency-associated genes, for
example Sox2, was variable and often required extended periods
of time (.8 days) for detection (not shown). This could reflect the
fact that genes such as Sox2 are subject to multiple layers of
repressive epigenetic modifications in B cells including DNA and
histone methylation [28,29] and late replication [30], or that they
require a higher threshold of activators for overt expression.
Similarities between gene expression profiles of human ES cell
lines and hB x mES fused cells prompted us to examine additional
markers that are expressed solely by either human or mouse ES
cells [31–34]. These included fibroblast growth factor receptors
(Fgfr1 and Fgfr2) and Fgf2 (expressed by human ES cells), Bmp4
and leukaemia inhibitory factor (Lif) receptor (expressed by mouse
ES cells) and SSEA4, a surface glycoprotein selectively expressed
by human ES cells [27] (Figure S2B). This analysis revealed that
reprogrammed cells expressed increasing amounts hFgfr1,h Fgfr2
and hFgf2 but did not express hBmp4 or hLifr or upregulate the
downstream kinase hJak3 (Figure 2B). Thus, these data show that
while dominant conversion is driven by mouse ES cells (that
express Bmp4 and Lifr prior to fusion, Figure S2A), reprogrammed
heterokaryons and hybrid cells show a remarkably different
expression profile resembling human, rather than mouse ES cell
lines. Consistent with this, fusion of mouse ES cells and human B
cells resulted in SSEA4 expression by 13–16% of the cells (days 2–
8 as shown in Figure 2C). Isolation of SSEA4-positive cells
confirmed that this subset contained successfully reprogrammed
cells that express hOct4,h Nanog and hCripto (Figure S2C), while
SSEA4-negative cells were not reprogrammed. The observation
that only a proportion of heterokaryons are successfully repro-
grammed, as judged by hOct4 DNA demethylation and SSEA4
expression, might partly explain why the levels of transcripts
encoding pluripotency factors are lower in reprogrammed cultures
than established hES cell lines.
To ask whether the reprogramming of human B cells by mouse
ES cells resets multi-lineage potential, hB x mES cultures were
treated with retinoic acid (RA) 6–8 days after cell fusion in order to
induce differentiation (Figure 3). Prior to RA treatment most cells
in hB x mES colonies showed alkaline phosphatase (AP) activity
(Figure 3A), and expressed human AP transcripts (not shown).
Hybrid colonies also expressed several pluripotency-associated
Author Summary
One of the most pressing objectives of medical research
today is the development of approaches to restore the
function of tissues damaged by accident or disease. An
important goal for this work is the isolation of stem cell
populations to replace missing or nonfunctioning cells.
Because problems of immune rejection are likely to occur
unless the recipient and donor stem cells are very closely
matched, a desirable strategy is to convert differentiated
cells (such as white blood cells) from patients into
immature tailored stem cell populations. Here, we have
experimentally fused human white blood cells and mouse
embryonic stem cells and shown that this reprograms
them to become stem-like. This kind of ‘‘differentiation
reversal’’ is shown to be rapid and stable. It requires the
stem cell–specific factor Oct4, but does not require Sox2.
This approach allows the identification of factors that are
required to reprogram human blood cells with the long-
term perspective to eventually generate patient-specific
stem cells.
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Nanog-specific antibody) and the human embryonic-specific
antigens SSEA4, TRA-1-60 and TRA-1-81 [27] (Figure S3).
Following treatment with RA, AP activity and expression of hOct4,
hNanog and hRex1 was reduced (Figure 3C), while morphological
heterogeneity within colonies increased. RA treatment induced the
expression of genes associated with extra-embryonic (hCdx2,
hHand1 and hGata6), endoderm (hSox7,h Hnf4 and hCollagenIVaI),
mesoderm (hMixl1,h Ebf and hMyoD) and ectoderm (hNestin,
Figure 3B) differentiation in hB x mES, but not in control hB cells
(Figure 3C, blue and black lines respectively). Differentiation also
resulted in increased DNA methylation of the hOct4 promoter
(Figure 3D) to levels similar with that seen in differentiated human
cells (Figure 1E). Taken together, these results show that
reprogramming of human B cells by mouse ES cells resets gene
expression and multi-lineage potential.
Interspecies Reprogramming of Human B Cells Requires
mOct4 but Not mSox2
Oct4 is part of the core regulatory circuitry in ES cells [35] and
it is essential for pluripotency and self-renewal [36]. To assess the
potential role of mouse-derived Oct4 as a dominant ‘trans’ acting
factor within inter-species heterokaryons we generated ES cells
expressing Flag-tagged mouse Oct4 protein (Figure 4A) and fused
these with human B lymphocytes (Figure 4B). Flag-tagged Oct4
(derived from mouse ES cells) was seen to accumulate within
human nuclei 3 to 6 hours after cell fusion (Figure 4B; complete
kinetic experiment shown in Figure S4A). In addition, Oct4
protein was present in heterokaryon nuclei (at 3 hours) before
transcription of hOct4 was initiated (at 24 hours). Thus, translo-
cation of the ES-derived Oct4 into human lymphocyte nuclei
precedes reprogramming.
Conversion of human fibroblasts to ES-like cells has been shown
to require the activation of at least four factors including Oct4,
Sox2 and either Nanog plus Lin28 [9] or Klf4 plus c-Myc [10].
Recently it was shown that mouse ES cells lacking Sox2, a factor
thought to be vital for preventing extra-embryonic differentiation,
can remain pluripotent provided with elevated Oct4 levels [37].
To investigate the relative importance of Oct4 and Sox2 in
reprogramming, mouse ES cells that are inducible null (Tet-off) for
mOct4 (ZHBTc4 [36]) or for mSox2 (2TS22C [37]) were used as
fusion partners with human B cells. These inducible null ES cell
lines were constructed and characterised previously [36,37] and
display a rapid (within 24 hours) and complete elimination of Oct4
or Sox2 gene/protein expression upon doxycycline (+Dox)
treatment. In our hands, pre-treatment of ZHBTc4 cells with
Dox for 6 and 12 hours, resulted in a progressive decrease in
mOct4 gene expression (Figure 4C), without significantly affecting
the expression of other pluripotency-associated genes in these cells
or the efficiency which they fuse with human B cells (Figure S4B).
Successful reprogramming, as judged by induction of several
human genes (Oct4, Nanog, Cripto, Dnmt3b, Sox2, Tle1, Tert and Rex1)
was however reduced (+6 hours) or eliminated (+12 hours) by pre-
treatment of ZHBTc4 cells with Dox (Figure 4D, a complete
kinetic analysis is provided in Figure S4C). Likewise, knocking
down mOct4 using short interference RNA (siRNA) in E14tg2a
mES cells (Figure S5A and Text S1) also abolished reprogram-
ming activity (Figure S5B). These results confirm that mOct4
expression is critically important for initiating successful repro-
gramming, in keeping with previous reports [7–10,38]. The
extinction of human lymphocyte-specific genes was however not
impaired by Oct4 removal (Figure S4C), a result that may support
previous findings that the activation and silencing of gene
expression programs in heterokaryons are mechanistically distinct
processes [13]. Eliminating mSox2 expression in the mouse ES cell
(Figure 5A, 2TS22C) had, in contrast, a relatively mild effect on
reprogramming efficiency (Figure 5B, compare values at 0, 12 and
24 hours of Dox treatment). Furthermore, reprogramming was
fully restored in fusions using 2O1 cells, a Sox2-deficient mES cell
line in which mOct4 expression is up-regulated [37] (Figure 5A,B
values shown in red and complete kinetics shown in Figure S6).
These data show that Oct4, but not Sox2, is critical for the
dominant reprogramming activity of mouse ES cells. Interestingly,
using 2O1 cells we observed the enhanced induction of hSox2
(Figure 5B, red arrow), a result that suggests that mouse-derived
Oct4 levels may be important for initiating hSox2 expression in
somatic nuclei.
ES-Derived mOct4 Is Dispensable for Maintaining the
Reprogrammed Status of Somatic Cells
To assess whether gene expression by the reprogrammed cell is
stable (self sustaining) or requires the continuous supply of factors
provided by the mouse ES cell, we generated hybrid cells between
lymphocytes and ES cells in which Oct4 expression could be
conditionally withdrawn (ZHBTc4, experimental outline depicted
in Figure 6A). In these experiments fusions were performed
between mouse lymphocytes carrying a silent, Oct4-driven GFP
transgene (GOF18DPE) and mouse ZHBTc4 ES cells, to allow
successfully reprogrammed hybrid cells to be identified on the
basis of GFP re-expression by day 10 (Figure 6A). Hybrid clones
contained a rearranged IgH locus, consistent with their derivation
from mouse B cells (Figure S7A and Text S1), displayed twice the
Figure 1. Pluripotent reprogramming of human B-lymphocytes by mouse ES cells is initiated in heterokaryons prior to nuclear
fusion and cell division. (A) Shows the experimental strategy used to generate interspecies heterokaryons (hB x mES). Human B-lymphocytes (hB)
and mouse embryonic stem cells (mES) were respectively labelled with the cell membrane dyes DiI and DiD and fused in the presence of
polyethylene glycol (PEG). Fused cells were FACS sorted and cultured under conditions that promote mES self-renewal. (B) Immunofluorescence
analysis of the kinetics of heterokaryon (cells in which parental nuclei share the same cytoplasm but remain discrete) and hybrid formation (where
both parental genomes occupy the same nucleus) following PEG induced fusion. In the lower panels hB-derived nuclei were distinguished by mouse
nuclei on basis of DAPI (blue) and human Lamin A/C staining (green), and actin staining (red) delineates individual cells. Confocal sections showing a
hB cell prior to fusion (left, day 0), a heterokaryon [one mouse (with DAPI intense foci) and one human nucleus (hLamin A/C positive)] (middle, day 2)
and a hybrid cell (right, day 3) are shown. Scale bar, 10 mm. n=100. (C) The expression of hES-specific genes (hOct4,h Nanog,h Cripto,h Dnmt3b,h Tle1,
hRex1) was assessed by quantitative RT-PCR analysis 0 to 8 days after cell fusion. Positive (hES-NCL1, black bars) and negative (hB) controls for this
analysis were included. (D) Activation of embryonic genes is accompanied by silencing of lymphocyte-specific genes (hCD19,h CD37,h CD20,h CD45
and hPax5), while a constitutively expressed gene hHprt remained detectable at similar levels at all time points. Data were normalised to hGapdh
expression. Error bars indicate the s.d. of 3 independent experiments. (E) Bisulfite genomic sequencing analysis of DNA methylation at the human
Oct4 promoter 0, 2, 4 and 8 days after cell fusion demonstrated the rapid de-methylation of Oct4 induced by fusion with mES cells. Human ES cells
(hES, cell line H1; lower panel) are shown as controls. The methylation pattern of Igf2/H19 imprinting control region (ICR) remained unaltered
throughout the experiment. The position of CpG sites relative to the transcriptional start site (TSS) is indicated. Open circles represent unmethylated
cytosines, black closed circles represent methylated cytosines and grey closed circles represent constitutively methylated cytosines. Regions 1, 2 and
3 indicate CpG sites that are part of the same PCR product.
doi:10.1371/journal.pgen.1000170.g001
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karyotypically stable over the study period (not shown). As
anticipated, hybrid cells expressed ZHBTc4-derived Oct4bgeo
transcripts and several pluripotency-associated genes, but did not
express B cell markers such as CD19, Pax5 and Ly108 (Figure S7B).
Two hybrid clones were selected for study (hybrid 4 and 12) and
were treated with Dox to selectively ablate expression of ZHBTc4-
derived Oct4bgeo (Figure 6C; Figure S7C shows the strategy used
to selectively detect Oct4bgeo transgene expression). Withdrawal
of ZHBTc4-derived Oct4 did not alter the expression of mNanog
and mSox2 in reprogrammed cells (Figure 6C), and did not
precipitate differentiation towards trophectoderm or the up-
regulation of mCdx2 and mHand1 expression [36] (Figure 6D
and Figure S7D); events that are induced by the removal of Oct4
from the parental ZHBTc4 line (Figure 6D right hand panel and
Figure 6E). Thus, our data show that reprogramming of
lymphocytes by mouse ES cells induces an epigenetically stable
(and heritable) resetting of gene expression in the lymphocyte
nucleus.
Discussion
In this study we show that reprogramming human lymphocytes
can be achieved using mouse ES cells as a cell fusion partner, a
process that induces the re-expression of endogenous human genes
normally associated with human blastocyst development and
human ES cell lines. Successful interspecies reprogramming is
initiated in heterokaryons prior to chromosome intermixing, and
generates cells that express human FGF signalling pathway
components and human ES-specific surface molecules such as
SSEA4, TRA-1-60 and TRA1-81. We show that this reprogram-
ming is critically dependent upon Oct4, since Oct4 deletion
abolishes the reprogramming capacity of mES cells. Conversion of
human B cells into ES-like cells results in the re-modelling of the
somatic genome with loss of DNA methylation at the hOct4 locus.
Importantly, once reprogramming is initiated by factors produced
by the dominant (ES) nucleus, we show that withdrawal of mOct4
does not compromise the phenotype of hybrid cells. This result
implies that the reprogrammed state, once initiated, is both self-
sustaining and heritable.
One surprising aspect of the reprogramming data shown here is
the rapidity of gene conversion and DNA demethylation that
occurs within heterokaryons. As successful reprogramming is only
achieved in a proportion of heterokaryons (,13%), it is likely that
partial DNA replication (or repair) is required for lymphocyte
conversion. Previous studies have shown that reprogramming in
experimental heterokaryons using adult cells from different
lineages [13,39], can be initiated before genome duplication and
cell division. Here we show that conversion of unipotent
lymphocytes towards multipotency is achieved in transient
heterokaryons prior to cell division. Re-activation of human Oct4
and Nanog by human nuclei, has been shown to occur rapidly upon
DNA de-methylation and Tpt1 activation induced by Xenopus
oocytes [21,40]. The rapid re-activation of endogenous pluripo-
tency-associated genes seen in inter-species heterokaryons is
consistent with transgene re-activation studies that have reported
Oct4gfp expression by MEFs [41] or NSCs [22] fused with mouse
ES or EC cells. Collectively these results may have an impact for
generating human ES-like cells. Proof that mouse ES cells can
dominantly reset the multi-lineage potential in human somatic
cells, together with evidence that this process begins prior to
nuclear fusion, suggests that improved methods for removing
mouse chromosomes from heterokaryons [42] may be applicable
for generating human stem cell lines. Alternatively, using
conditionally targeted mouse ES cells to dissect the roles of
individual proteins thought to be critical for multipotent
reprogramming, may provide a rationale for using distinct protein
cocktails to directly re-set lineage potential.
In the experiments presented here we have shown that
reprogrammed human cells express a profile of transcripts,
signalling molecules and surface antigens that are similar to those
seen in human ES cells, and different from mouse ES cells. This
suggests that an early human embryonic ‘‘program’’ of gene
expression is initiated in human nuclei by trans-acting (mouse)
factors. Differences between the expression profiles of mouse ES
cells and human reprogrammed nuclei probably reflect discrep-
ancies in cis-acting regions between the mouse and human
genomes. In agreement with this idea, a study in which the entire
hTert gene was introduced into mice, showed expression of the
transgene was similar to endogenous hTert in humans, rather than
mouse endogenous mTert [43]. It is interesting to speculate that
some of the well-publicised differences between human and mouse
ES cells may indeed reflect intrinsic species dissimilarities, rather
than temporal differences in stem cells isolation [44,45]. We show
that after fusion of human lymphocytes to mouse ES cells (that are
Lif and Bmp dependent), human ES-like cells are generated that
express FGF signalling components (and are not dependent of Lif/
Bmp). Thus, our data suggest that differences between human and
mouse ES cells may reflect distinct signalling and transcriptional
networks, rather than necessarily when or where they were
isolated during embryogenesis.
We show here that Sox2, in contrast to Oct4, is not required to
convert human lymphocytes into a multi-potent state. This
observation contrasts with results obtained previously using iPS
strategies to reprogram mouse and human fibroblasts [7–10,38],
mouse hepatocytes and stomach cells [46] and mouse B-
lymphocytes [47]. Whether this is because of differences relating
to the overexpression of transcription factor cocktails used in iPS,
or that reprogramming occurs over an extended time period
(pluripotency-associated genes such as Oct4, Nanog and Sox2 are
reactivated after 2 weeks of transduction [48,49]), is not known.
However, as Sox2 was recently shown to be dispensable for the
activation of Oct–Sox enhancers in mouse ES cells [37], it is also
possible that additional Sox family members such as Sox4, Sox11
and Sox15, may have redundant functions with Sox2 in
reprogramming. Interestingly, by enhancing Oct4 levels in Sox2-
Figure 2. Gene expression in reprogrammed lymphocytes resembles human rather than mouse ES cell lines. (A) Quantitative RT-PCR
analysis of the relative levels of gene expression in several human (NCL1, H1, H7 and H9), mouse (OS25, CCE, E14 and ZHBTc4) ES cell lines and in
reprogrammed lymphocytes (hB x mES) at 0, 2, 4 and 8 days after cell fusion. Human ES lines (left panel) and hB x mES (right panel) gene expression
data were normalised to hGapdh. Mouse ES lines (middle panel) gene expression data were normalised to mGapdh. Error bars indicate the s.d. of 3–4
independent experiments. (B) After cell fusion, genes involved in the maintenance of undifferentiated human ES cells (hFgfr1, hFgfr2 and hFgf2) were
activated while genes selectively expressed by mouse ES cells (hBmp4,h Lifr and hJak3) were not induced. Data were normalised to hGapdh
expression. Error bars indicate the s.d. of 3 independent experiments. (C) Heterokaryons resulting from human B cell and mouse ES cell fusions (hB x
mES) were stained for SSEA4 at 0, 2, 4 and 8 days and expression was analysed by flow cytometry. The results showed that 13.5% (day 2), 16.6% (day
4) and 15.8% (day 8) of total heterokaryons expressed SSEA4, as delineated by the rhomboid gates. Mean intensity fluorescence of positive cells is
indicated.
doi:10.1371/journal.pgen.1000170.g002
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by reprogrammed human B cells. Recent genome-wide studies
have shown that Sox2 is a direct target of Oct4 in both human [35]
and mouse [50] ES cells, a fact that could explain why hSox2 is
efficiently reprogrammed using ES cells that overexpress mOct4.I n
our hands, overexpression of exogenous Oct4 in lymphocytes did
not induce pluripotent conversion (Pereira & Terranova, unpub-
lished results), a finding that argues that additional chromatin
remodelling factors, perhaps including those known to interact
with Oct4 [51,52] or associated with the process of DNA
demethylation, may be critical for successful reprogramming.
Collectively, our data show that interspecies heterokaryons can
Figure 3. Multi-lineage potential is reset in reprogrammed human lymphocytes. (A) Hybrid colonies resulting from fusion of human B cells
(hB) and mouse ES cells (hB x mES) showed alkaline phosphatase activity (pink), that was reduced upon retinoic acid (RA) treatment. (B) RA treatment
of hybrid colonies (day 6) generated cells that expressed Nestin (green) detected by immunostaining using an antibody specific for human (and not
mouse) Nestin protein. DAPI counterstaining (blue) is shown. Scale bars, 50 mm. (C) Quantitative RT-PCR analysis of gene expression upon RA
treatment of hybrid cells (blue line) showed that levels of pluripotency genes (hOct4,h Nanog and hRex1) declined while differentiation-associated
genes were upregulated [extra-embryonic (hCdx2,h Hand1 and hGata6), endoderm (hSox7,h Hnf4 and hCollagenIVaI), mesoderm (hMixl1,h Ebf and
hMyoD) and ectoderm (hNestin)]. Unfused hB cells were included as controls (black line). Data were normalised to hGapdh expression. (D) Bisulfite
genomic sequencing analysis of DNA methylation at the human Oct4 promoter 8 days after RA treatment showed the re-methylation of the Oct4
promoter while the Igf2/H19 imprinted control region (ICR) remains unaltered. The position of CpG sites relative to the transcriptional start site (TSS) is
indicated. Open circles represent unmethylated cytosines, black closed circles represent methylated cytosines and grey closed circles represent
constitutively methylated cytosines.
doi:10.1371/journal.pgen.1000170.g003
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PLoS Genetics | www.plosgenetics.org 7 September 2008 | Volume 4 | Issue 9 | e1000170Figure 4. Oct4 is required for successful reprogramming. (A) Mouse ES cells expressing a tagged Oct4 protein (Flag-mOct4) were generated
by insertion of Flag-tagged mouse Oct4 cDNA in E14tg2a ES cells (parental cell line). Western blotting with anti-Oct4 and anti-Flag antibodies
confirmed the presence of Flag-tagged Oct4 protein by transduced cells. Equivalent protein loading is shown with Lamin B detection. (B)
Immunofluorescence analysis of cultured heterokaryons 6 hours after cell fusion showed the presence of ES cell-derived Oct4 (Flag-Oct4, green) in a
human nucleus (arrowed). Human nuclei were distinguished from mouse nuclei on basis of diffuse versus punctuate DAPI staining (blue),
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PLoS Genetics | www.plosgenetics.org 8 September 2008 | Volume 4 | Issue 9 | e1000170respectively. Actin labelling (red) delineates the cell membrane. Images are confocal sections of heterokaryons containing a single mouse (with DAPI
intense foci) and a single human nucleus. Scale bar, 10 mm. (C) In ZHBTc4 ES cells endogenous Oct4 was replaced by an inducible transgene
(Oct4bgeo) which can be downregulated by addition of doxycycline (Dox) [36]. Quantitative RT-PCR analysis showed that 6 hours (+6) and 12 hours
(+12) after Dox treatment, mOct4 was progressively downregulated, while expression of other pluripotency-associated genes (mNanog,m Cripto,
mRex1 and mSox2) was largely unaffected. (D) ES cells expressing normal levels of Oct4 (-), partially reduced (Dox
+6) or lacking Oct4 expression
(Dox
+12) were fused to hB-lymphocytes. Successful reprogramming was assessed by quantifying the abundance of human ES-associated transcripts
two days after fusion by qRT-PCR. Activation of pluripotency genes in hB-lymphocytes was reduced or impaired when Oct4 was ablated. Data were
normalised to Gapdh expression. Error bars indicate the s.d. of 2–3 independent experiments.
doi:10.1371/journal.pgen.1000170.g004
Figure 5. Sox2 is dispensable for reprogramming. (A) In 2TS22C ES cells endogenous Sox2 is replaced by an inducible transgene (Sox2Zeo)
which can be downregulated by addition of doxycycline (Dox) [37]. Quantitative RT-PCR analysis showed that 12 hours (+12) and 24 hours (+24) after
Dox treatment, mSox2 was downregulated while expression of other pluripotency-associated genes (mNanog,m Cripto,m Rex1 and mOct4) continued
to be expressed. 2O1 ES cells are Sox2-deficient mES cells (asterisk) in which mOct4 expression is up-regulated (red bars). (B) ES cells expressing Sox2
(-), Sox2 depleted cells (Dox
+12, Dox
+24) and 2O1 cells were fused to hB-lymphocytes. Successful reprogramming was assessed by quantifying the
abundance of human ES-associated transcripts two days after fusion by qRT-PCR. Activation of pluripotency genes in hB-lymphocytes occurs in the
absence of mSox2. An elevated induction of hSox2 using 2O1 cells as a fusion partner is highlighted by an arrow (red). All data were normalised to
Gapdh expression and error bars indicate the s.d. of 2–3 independent experiments.
doi:10.1371/journal.pgen.1000170.g005
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PLoS Genetics | www.plosgenetics.org 9 September 2008 | Volume 4 | Issue 9 | e1000170Figure 6. Reprogramming is self-sustaining and can be maintained in the absence of ES-derived Oct4. (A) To address whether
reprogramming is stable or subject to reversion, we ablated Oct4 expression after hybrid formation. ZHBTc4 ES cells [mES with endogenous Oct4
replaced by an inducible transgene (Oct4bgeo) which can be downregulated by addition of doxycycline (Dox)] were fused with mouse B-
lymphocytes (mB) carrying a GFP transgene under the control of Oct4 promoter (GOF18DPE). Reprogramming of mB results in the re-activation of
GFP in hybrid colonies (d10, lower panels). Kinetic analysis of single cells (upper panels) showed that transgene re-activation occurs in heterokaryons
(day 2, 2 arrows), and hybrid cells (day3, arrowhead). mB cells are shown as negative controls. Nuclei were visualised with DAPI staining (blue). Scale
bars, 10 mm. (B) Hybrid clones (mES x mB, 4n) that re-expressed GFP were isolated and analysed by FACS. mES, mB and mES x mB hybrid cells
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allowing the factors that are required to directly induce
pluripotency to be defined individually and in combination.
Materials and Methods
Cell Culture
EBV-transformed hB clones were maintained in RPMI
supplemented with 10% foetal calf serum (FCS), 2 mM L-
glutamine and antibiotics (10 mg/ml Penicillin and Streptomycin).
The Abelson transformed Oct4-GFP B-cell line was derived from
the Oct4-GFP transgenic mice (GOF18DPE) [53] bone marrow,
cloned and grown in RPMI supplemented with 20% FCS, non-
essential amino acids, L-glutamine, 50 mM 2-mercaptoethanol,
antibiotics and IL-7 (5 ng/ml; R&D systems, Minneapolis, MN).
Mouse ES cells were grown and maintained undifferentiated either
on irradiated SNL feeder layers (E14Tg2a, Hprt
2/2 ES cells; CCE
and E14) or directly on 0.1% gelatin-coated surfaces (OS25,
ZHBTc4 and 2TS22C feeder-free ES cell lines). ES cells were
grown in KO-DMEM medium plus 10% FCS, non-essential
amino acids, L-glutamine, 2-mercaptoethanol, antibiotics and
1000 U/ml of leukaemia inhibitory factor (ESGRO-LIF). Feeder-
free ES cell lines were cultured in GMEM-BHK21 medium plus
10% FCS, non-essential amino acids, sodium pyruvate, sodium
bicarbonate, 2 mM L-glutamine, 2-mercaptoethanol, antibiotics
and 1000 U/ml of LIF. Doxycycline (1 mg/ml, Sigma) or Retinoic
acid (10
26 M, Sigma) were added to the media when indicated.
The Flag-mOct4 cell lines were derived by the overexpression of
Flag-tagged mouse Oct4 in E14tg2a ES cells. Briefly, mouse Oct4
cDNA was cloned in the pDFLAG-cDNAIII vector (Invitrogen).
The cDNA, including two flag sequences at the 59 end, was
excised and sub-cloned into a suitable vector for expression in ES
cells (pCBA), with expression driven by the chicken b-actin
promoter. The vector was then linearised and transfected by
electroporation into mouse ES cells. G418 selection (400 mg/ml;
Invitrogen) was applied 48 hrs after and resistant clones were
manually picked and screened by Western blot. Human ES cell
lines H1, H7 and H9 cells [27] were cultured in medium
conditioned by mitotically inactivated MEFs supplemented with
8 ng/ml bFGF (Peprotech, London, UK) on matrigel-coated
plates, as previously described [54]. Cells were routinely passaged
at a 1:3 dilution by treatment with 200 U/ml collagenase IV
(Invitrogen, Carlsbad, CA) and mechanical dissociation.
Experimental Heterokaryons
Heterokaryons were generated by fusing ES cells and B-
lymphocytes using 50% polyethylene glycol, pH7.4 (PEG 1500;
Roche Diagnostics, Mannheim, Germany). Briefly, ES cells and
hB-lymphocytes were respectively labelled with Vibrant 1,19-
dioctadecyl-3, 3, 39,3 9 tetramethylindodicarbocyanine (DiD) and
1,19-dioctadecyl-3, 3, 39,3 9-tetramethylindocarbocyanine perchlo-
rate (DiI) cell labelling solutions (Molecular Probes, Eugene, OR).
Cells were resuspended at 1610
6 cells/ml in DMEM and labelled
with 5 ml/ml of dye at 37uC, 15 min. ES and hB were then mixed
in an appropriate ratio (ES:hB ratio 1:1; ES:Oct4-GFPB ratio 1:5),
and were washed twice in PBS. The supernatant was completely
removed and 1 ml of PEG (37uC) was added to the pellet of cells
over 60 sec and incubated at 37uC for 90 sec with constant
stirring. Then, 4 ml of serum-free medium (DMEM) were
carefully added over a period of 3 min, followed by 10 ml of
DMEM and incubation at 37uC for 3 min. After centrifugation
(1350 rpm, 5 min), the pellet was allowed to swell in complete
medium for 3 min. Cell mixtures were then resuspended and
cultured under conditions promoting the maintenance of undif-
ferentiated mouse ES cells at 0.5610
6 cells/cm
2. To eliminate
unfused hB cells, Ouabain (10
25 M; Sigma) was added to the
medium 4 hours after cell fusion. When OS25, ZHBTc4 and
2TS22C cell lines were used, proliferating ES cells were eliminated
by the addition of 10
25 M Ara-C (Cytosine b-D arabino
furanoside; Sigma) 4–6 hours after fusion and then removed after
16 hours. When E14tg2a ES cells or derivatives were used, HAT
(20 mM hypoxanthine, 0.08 mM aminopterine and 3.2 mM
thymidine; Sigma) was added to the medium 24 hours after fusion.
Quantitative RT-PCR Analysis
RNA extraction was performed using RNA-BEE reagent (Tel-
Test Inc., Friendswood, TX) and residual DNA was eliminated
using the DNA-free kit (Ambion, Austin, TX). 3 mg of total RNA
was then reverse transcribed using Superscript First-Strand
Synthesis system (Qiagen) with oligo (dT)12-18 (Invitrogen). cDNAs
of interest were then quantified using real-time qPCR amplifica-
tion. Real-time PCR analysis was carried out on a Opticon DNA
engine using Opticon Monitor software (MJ Research Inc.,
Waltham, MA), running the following program: 95uC for
15 min, then 40 cycles of 94uC for 15 sec, 60uC for 30 sec,
72uC for 30 sec, followed by plate-read. PCR reactions included
26 Sybr-Green PCR Mastermix (Qiagen), 300 nM primers and
2 ml of template in a 35 ml reaction volume. Each measurement
was performed in triplicate and data normalised according to
Gapdh expression. Primers were designed with Primer Express
software (Applied Biosystems) and tested for the specific detection
of human transcripts (and not mouse). Standard curves were
calculated on serial dilutions of positive control cDNA. Primer
sequences used for this analysis are indicated in Table S1.
Bisulfite Genomic Sequencing
Bisulfite modification of DNA was carried out with the EZDNA
methylation kit (Zymogenetics Inc., Orange, CA) according to
manufacturer’s recommendations. PCR primers that recognise
bisulfite-converted human DNA only are listed in Table S1.
Amplified products were cloned into pCR2 (Invitrogen) and ten
clones were randomly picked and sequenced.
Antibodies, Imaging, and FACS Analysis
For immunofluorescence and FACS analysis, the following
antibodies and dilutions were used: mouse monoclonal anti-
human Lamin A/C (VP-L550; Vector Laboratories Inc., Burlin-
unstained (left panel) or stained with propidium iodide (right panel) to assess GFP expression and DNA content, respectively. (C) Hybrid clones (4 and
12) were treated with Dox to ablate ES-derived Oct4, and quantitative RT-PCR confirmed downregulation of Oct4bgeo transcript (upper panels).
Removal of mES-derived Oct4bgeo in hybrid clones did not affect gene expression of pluripotency-associated transcripts (lower panels; mOct4,
mNanog and mSox2) after 96 hours of Dox treatment. (D) No differentiation was observed after Oct4 removal in hybrid cells. mRex1 expression was
retained and the extra-embryonic markers mHand1 and mCdx2 were not induced. In ZHBTc4 ES cells (open bars) upon Dox treatment, mHand1 and
mCdx2 were induced [36] and are shown for comparison. Data were normalised to mGapdh expression. Error bars indicate the s.d. of 3 independent
experiments. (E) Western blotting with anti-Oct4 antibody confirmed that Oct4 protein is rapidly removed after Dox treatment of ZHBTc4 ES cells
(lower panel) but remains detectable at all times in hybrid cells (upper panels). Equivalent protein loading is shown with Lamin B detection.
doi:10.1371/journal.pgen.1000170.g006
Reprogramming Lymphocytes for Pluripotency
PLoS Genetics | www.plosgenetics.org 11 September 2008 | Volume 4 | Issue 9 | e1000170game, CA) at 1:100 dilution; rabbit polyclonal anti-GFP (A11122;
Molecular Probes) at 1:200 dilution; mouse monoclonal anti-
human SSEA4 (MC-813-70; Developmental Hybridoma Studies
Bank, Iowa City, IA) at 1:3 dilution; mouse monoclonal anti-
human TRA-1-60 and TRA-1-81 (MAB4360 and MAB4381;
Chemicon International, Temecula, CA) at 1:12 and 1:20
dilutions, respectively; rabbit polyclonal anti-human Nanog and
Nestin (ab21624 and ab28944; Abcam Ltd., Cambridge, UK) at
1:100 dilution; mouse monoclonal anti-Flag (F3165, Sigma) at
1:1000 dilution. Secondary antibodies conjugated with fluoro-
chromes were purchased from Molecular Probes and used at 1:400
dilution. Immunofluorescence was performed as previously
described [13]. Mouse and human nuclei were distinguished in
the resulting heterokaryons by counterstaining with 4,6-diamidino-
2-phenylindole (DAPI) and human Lamin A/C staining. Individ-
ual cells were delineated by F-actin staining (Phalloidin; A12380,
Molecular Probes). For alkaline phosphatase assays, hybrid
colonies 8 days after cell fusion were stained with alkaline
phosphatase assay kit (Sigma). All slides were analyzed on a Leica
TCS SP5 confocal microscope and processed with Leica software
and Adobe Photoshop. Images of live GFP fluorescent hybrid
colonies and alkaline phosphatase staining were collected using a
Leica DM IRE2 microscope running Metamorph software. For
FACS analysis a FACScalibur (BD Biosciences) with CellQuest
software was used. FACS purification was performed using a
FACSAria cell sorter. Western blot analysis was performed as
previously described [55] using a goat anti-Oct3/4 polyclonal
antibody (sc-8628; Santa Cruz Biotechnology Inc., Santa Cruz,
CA) or a mouse anti-Flag monoclonal antibody. As a loading
control, blots were incubated with anti-Lamin B polyclonal
antibody (sc-6216; Santa Cruz Biotechnology Inc.). Each lane
contained 20 ı `g total protein.
Supporting Information
Figure S1 Characterisation of heterokaryon reprogramming of
fused hB x mES cells. (A) Human B-lymphocytes (hB) and mouse
embryonic stem cells (mES) were respectively labelled with the cell
membrane dyes DiI and DiD and fused in the presence of
polyethyleneglycol(PEG).Fusedcells,identified bydouble-labelling
(upper right quadrant), were sorted by FACS and cultured. (B)
Mouse and human nuclei were distinguished by FISH using probes
specific for mouse c-satellite DNA (red) or human a-satellite DNA
(green), and DAPI counterstained (blue). Confocal sections of
human B cells (hB) and mouse ES cells (mES) before and after cell
fusion (hB x mES) are shown. Heterokaryons (cells in which
parental nuclei share the same cytoplasm but remain discrete, day 1
and 2) were identified up to 2 days after fusion, but by day 3 hybrid
formation (where genomes are mixed in the same nucleus, day 3)
was detected. Scale bar, 10 mm. (C) Expression of human ES-
specific (hOct4,h Nanog) and human lymphocyte-specific (hCD20,
hCD45) transcripts detected by RT-PCR using human-specific
primers. Prior to fusion, hB cells expressed hGapdh,h CD20 and
hCD45 but not embryonic stem cell-specific genes. Following
heterokaryon formation (hB x mES d2), human pluripotency-
associated geneshOct4 and hNanogwereexpressed(upperpanel) and
hCD20 and hCD45 were extinguished (lower panel). mES, -RT and
H2O were used as negative controls and human embryonic stem
cells (hES) as a positive control. hGapdh was used to standardise
input. (D) Expression of human hTert transcripts detected by qRT-
PCR 0 to 8 days after cell fusion using human-specific primers.
Positive (hES-NCL1, black bars) and negative (hB) controls for this
analysis were included. Data were normalised to hGapdh expression.
Error bars indicate the s.d. of 3 independent experiments.
Found at: doi:10.1371/journal.pgen.1000170.s001 (5.32 MB TIF)
Figure S2 Differences between human and mouse ES cells and
the identification of SSEA4 positive reprogrammed cells. (A)
Expression of Fgfr1, Fgfr2, Fgf2, Bmp4, Lifr, and Jak3 was assessed
by qRT-PCR in human ES cells (hES, NCL1), mouse ES cells
(mES) and human B-lymphocytes (hB). Fgfr1, Fgfr2, and Fgf2 were
uniquely expressed by human ES cells. (B) FACS analysis showed
that .90% of hES cells (H1 cell line) expressed SSEA4, while hB
and mES do not (2.1% and 1.5% respectively). A proportion of
heterokaryons showed SSEA4 expression (15.8%) 8 days after cell
fusion (hB x mES d8). (C) FACS sorting of SSEA4 positive cells co-
purifies reprogrammed cells that express hOct4,h Nanog, and
hCripto, as assessed by qRT-PCR. Data were normalised to Gapdh
expression.
Found at: doi:10.1371/journal.pgen.1000170.s002 (0.74 MB TIF)
Figure S3 Expression of human-specific embryonic antigens in
hybrid cells. Human B cells (hB) and mouse ES cells (mES) were
fused and the resulting colonies (hB x mES, day 8) expressed
hNanog protein (red) and the human ES-specific antigens SSEA4,
TRA-1-81 and TRA-1-60 (green) as assessed by immunofluores-
cence. Control hB cells did not express any of the markers. DAPI
staining is shown in blue. Images are single confocal sections. Scale
bar, 50 mm.
Found at: doi:10.1371/journal.pgen.1000170.s003 (5.14 MB TIF)
Figure S4 Kinetic analysis of Oct4 protein distribution in
heterokaryons and the importance of Oct4 for successful
reprogramming. (A) Flag-mOct4 ES cells were fused to hB cells
and Oct4 protein detected by immunofluorescence at 0, 1, 3, 6, 9,
and 12 hours with Oct4 or Flag antibodies (green). Heterokaryons
were scored according to the following Oct4 distribution: Oct4
protein not detected (Negative), stronger staining in mES-derived
nucleus than hB nucleus (mES.hB), nuclei equally labelled
(mES=hB), stronger in the human nucleus (mES,hB). Confocal
sections of representative heterokaryons from each of the
categories are shown (upper panels). Human nuclei were
distinguished from mouse nuclei on basis of diffuse versus
punctuate DAPI staining (blue), respectively. Actin labelling (red)
delineates the cell membrane. Scale bar, 10 mm. n=100. (B) The
ability of mouse ES cells to fuse to human B cells is unaffected by
doxycicline (Dox) treatment. ZHBTc4 and hB cells were labelled
(with DiD and DiI, respectively) and PEG-fused. Fusion
efficiencies were obtained by FACS, as a percentage of double-
labelled cells. (C) ZHBTc4 ES cells expressing Oct4 (black bars), or
in which Oct4 expression has been partially or completely ablated
(grey and white bars, respectively) were fused to hB-lymphocytes.
The activation of human ES-specific genes (hOct4,h Nanog,h Cripto,
hDnmt3b,h Sox2,h Tle1,h Tert, and hRex1) and silencing of
lymphocyte-specific genes (hCD19,h CD45, and hCD37) were
quantified by qRT-PCR over the period of 3 days after cell fusion.
hHprt was added as a control gene. Data were normalised to
hGapdh expression. Error bars indicate the s.d. of 2–3 independent
experiments.
Found at: doi:10.1371/journal.pgen.1000170.s004 (3.61 MB TIF)
Figure S5 siRNA-mediated knock-down of mOct4 abolishes
reprogramming. (A) E14tg2a ES cells were transfected with either
mOct4-siRNA or target-less-siRNA (a negative control siRNA
designed to have no expected targets in human and mouse cells)
vectors. 48 hours later, transfected cells (GFP+) were FACS sorted
and analysed by quantitative RT-PCR analysis. mOct4-siRNA
targeted cells showed a .90% reduction in Oct4 transcript levels
as compared to cells transfected with target-less-siRNA (control).
(B) E14tg2a ES cells expressing mOct4-siRNA or control-siRNA
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assessed by quantifying the abundance of human ES-associated
transcripts (hNanog and hCripto) two days after fusion by qRT-
PCR. Successful reprogramming judge by the activation of human
pluripotency-associated transcripts was abolished by pre-treatment
of mES cells with Oct4-siRNAs. Data were normalised to Gapdh
expression. Error bars indicate the s.d. of 2 independent
experiments.
Found at: doi:10.1371/journal.pgen.1000170.s005 (0.82 MB TIF)
Figure S6 Kinetic of human lymphocyte reprogramming by
mES cells after Sox2 ablation. 2TS22C (black bars), Sox2 depleted
cells (grey and white bars; Dox 12 and 24 hours, respectively) and
2O1 cells (red bars; Sox2-deficient mES cells in which mOct4
expression is constitutively up-regulated) were used as fusion
partners with hB cells and reprogramming was assessed by
quantification of human-ES transcripts (hOct4,h Nanog,h Cripto,
hDnmt3b,h Sox2,h Tle1,h Tert and hRex1) using qRT-PCR over 3
days after cell fusion. hHprt was added as a control gene. Data
were normalised to hGapdh expression. Error bars indicate the s.d.
of 2–3 independent experiments.
Found at: doi:10.1371/journal.pgen.1000170.s006 (0.59 MB TIF)
Figure S7 Characterisation of mouse embryonic hybrid cells. (A)
Contribution of the lymphocyte genome within hybrid cells was
confirmed by detection of a rearranged IgH locus (D–J region).
IgH rearrangement was seen in B-lymphocytes (mB), hybrid cells
(mES x mB) but not in mES cells. The rearranged DNA can be
detected by PCR amplification and visualized on the gel as a
750 bp band. (B) Lymphocyte-specific genes (mCD19,m Pax5, and
mLy108) were not detected in hybrid cells although ES-specific
genes (mOct4,m Nanog,m Sox2,m Rex1, and mUtf1) remain
detectable by RT-PCR. (C) Specific detection of Oct4 transgene
(Oct4bgeo) by RT-PCR with primers within bgeo cassette, which
specifically amplify ZHBTc4-derived Oct4 but not endogenous
mOct4. mES and mB cells were included as controls. mGapdh was
used to standardise input. (D) Doxycycline (Dox) treatment of
ZHBTc4 ES cells results in morphological changes characteristic
of trophectoderm differentiation (upper panel). These were not
observed in hybrid clones 4 and 12 under the same conditions.
GFP protein (Oct4 promoter-driven) remains detectable in hybrid
cells throughout the experiment, as assessed by immunofluores-
cence.
Found at: doi:10.1371/journal.pgen.1000170.s007 (7.86 MB TIF)
Table S1 Primers used in this study.
Found at: doi:10.1371/journal.pgen.1000170.s008 (0.17 MB
DOC)
Text S1 Supplementary methods.
Found at: doi:10.1371/journal.pgen.1000170.s009 (0.04 MB
DOC)
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